OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGRAFT NOD-SCID IL2RGNULL (NSG) MOUSE MODEL: A POTENTIAL TARGETED AGENT IN THE TREATMENT OF PMBL. (October 2022)

Record Type:: Journal Article
Title:: OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGRAFT NOD-SCID IL2RGNULL (NSG) MOUSE MODEL: A POTENTIAL TARGETED AGENT IN THE TREATMENT OF PMBL. (October 2022)
Main Title:: OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGRAFT NOD-SCID IL2RGNULL (NSG) MOUSE MODEL: A POTENTIAL TARGETED AGENT IN THE TREATMENT OF PMBL
Authors:: Chu, Y.
Awasthi, A.
Lee, S.
Edani, D.
Yin, C.
Hochberg, J.
Shah, T.
Chung, T.
Ayello, J.
van de Ven, C.
Klein, C.
Lee, D.
Cairo, M.
Abstract:
Is Part Of:: Leukemia research. Volume 121(2022)Supplement
Journal:: Leukemia research
Issue:: Volume 121(2022)Supplement
Issue Display:: Volume 121, Issue 2022 (2022)
Year:: 2022
Volume:: 121
Issue:: 2022
Issue Sort Value:: 2022-0121-2022-0000
Page Start:: S14
Page End:
Publication Date:: 2022-10
Subjects:: Leukemia -- Periodicals
Leukemia -- Periodicals
Leucémie -- Périodiques
Leukemia
Periodicals
Electronic journals
Electronic journals
616.9941905
Journal URLs:: http://www.sciencedirect.com/science/journal/01452126 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0145-2126(22)00211-9 ↗
Languages:: English
ISSNs:: 0145-2126
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5185.270000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24198.xml